SCHEMBL20218428

SCHEMBL20218428

CC1CN(c2ccc(N)cn2)CCN1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIN2D O15399 1/20 0.44
▸ GRIN3B O60391 1/20 0.44
▸ GRIN1 Q05586 1/20 0.44
▸ GRIN2A Q12879 1/20 0.44
▸ GRIN2B Q13224 1/20 0.44
▸ GRIN2C Q14957 1/20 0.44
▸ GRIN3A Q8TCU5 1/20 0.44
▸ FGFR1 P11362 1/20 0.40
▸ FGFR2 P21802 1/20 0.40
▸ OGA O60502 1/20 0.40
▸ HDAC1 Q13547 9/20 0.40
▸ GRM1 Q13255 3/20 0.39
▸ ADRA2A P08913 1/20 0.38
▸ ADRA2B P18089 1/20 0.38
▸ ADRA2C P18825 1/20 0.38
▸ HDAC3 O15379 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ SLC6A4 P31645 1/20 0.37
▸ SLC6A3 Q01959 1/20 0.37
▸ MAPKAPK3 Q16644 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15858000 0.82 GRM1 (0.55) FGFR1FGFR2GRM1ADRA2AADRA2B
SCHEMBL27843669 0.80 GRIN2D (0.41) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL25840185 0.79 HRH3 (0.47) FGFR1FGFR2HDAC1GRM1ADRA2A
SCHEMBL23544820 0.79 ACACB (0.42) FGFR1FGFR2OGAHDAC1GRM1
SCHEMBL23444507 0.79 ADRA2A (0.44) FGFR1FGFR2HDAC1GRM1ADRA2A
SCHEMBL20483690 0.79 HDAC1 (0.50) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL20483691 0.79 HDAC1 (0.50) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL25191126 0.79 HDAC1 (0.50) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL15858041 0.78 GAA (0.53) CYP2C9
SCHEMBL14597411 0.78 SMO (0.52) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2773634-B1 ROD-LIKE HEPATITIS C VIRUS INHIBITORS CONTAINING THE FRAGEMENT {2-[4-(BIPHENYL-4-YL)-1H-IMIDAZO-2-YL]PYRROLIDINE-1-CARBONLYMETHYL}AMINE THERAVANCE BIOPHARMA R&D IP LLC (US) 2018-06-06 — — EP disclosed
Send feedback